Free Trial
NASDAQ:CLYM

Climb Bio Q3 2024 Earnings Report

Climb Bio logo
$1.35 0.00 (0.00%)
As of 04:00 PM Eastern

Climb Bio EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Climb Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Climb Bio Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
9:30AM ET

Upcoming Earnings

Climb Bio's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Climb Bio Earnings Headlines

Climb Bio Appoints Cindy Driscoll as Finance VP
Why Volatility Keeps Coming Back — And How I Trade It
Volatility isn’t the enemy — it’s the opportunity. While most traders panic during market swings, Jeff Clark uses a three-step method to target quick wins from VIX spikes and sudden price moves. It works in any market direction… and he’s showing how it works in a free video, available now.
CLYM Climb Bio, Inc.
BTIG sets Climb Bio stock Buy rating, $7 target
See More Climb Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Climb Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Climb Bio and other key companies, straight to your email.

About Climb Bio

Climb Bio (NASDAQ:CLYM) is a clinical-stage biotechnology company focused on the discovery and development of targeted protein degraders for the treatment of cancer and other serious diseases. The company is leveraging an integrated drug discovery platform that combines medicinal chemistry, structural biology and proprietary assays to identify small molecules capable of directing disease-causing proteins to the cell’s natural degradation machinery. With a primary emphasis on oncology, Climb Bio’s lead programs are designed to address high-unmet-need targets that have historically proven difficult to modulate with traditional small-molecule inhibitors or biologics.

Since its formation as an independent public company, Climb Bio has built a pipeline that spans multiple therapeutic modalities and target classes. Its research and development efforts are supported by state-of-the-art laboratories in the United States, where multidisciplinary teams work on early-stage discovery as well as translational research. The company has also established strategic partnerships to broaden its scientific capabilities and expedite the advancement of its most promising candidates toward clinical evaluation. Through these collaborations, Climb Bio aims to capitalize on external expertise while retaining core control over its proprietary chemistry and screening platforms.

Climb Bio was founded by a group of industry veterans and academic scientists with deep experience in drug discovery, structural biology and oncology. The senior management team includes executives who have previously led successful biotech ventures and overseen late-stage clinical programs. Based in the U.S., with outreach to select research centers in Europe and Asia, the company combines global scientific collaboration with a nimble organizational structure. This approach is intended to streamline decision-making and foster rapid progress from target discovery through clinical development.

View Climb Bio Profile

More Earnings Resources from MarketBeat